Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Tomas Kauer - Moderator

Sep 9, 2024 - 01:00

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Tags:

Previous Article

Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan w...

Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled a...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Tomas Kauer - Moderator

Related Posts

Tech’s emissions may be way higher than disclosed due to ‘creative accounting’ of carbon

Tech’s emissions may be way higher than disclosed due t...

Tomas Kauer - Mode... Sep 17, 2024

Apple Intelligence is coming to the EU in April 2025

Apple Intelligence is coming to the EU in April 2025

Tomas Kauer - Mode... Oct 29, 2024

JPMorgan could take over Goldman’s Apple Card business

JPMorgan could take over Goldman’s Apple Card business

Tomas Kauer - Mode... Sep 18, 2024